The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
Official Title: Phase 1 Open Label Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 as a Single Agent in Patients With Refractory Solid Tumors
Study ID: NCT01544322
Brief Summary: The purpose of this study is to determine the tolerability of ME-344, find the maximum tolerated dose, and the safety profile in patients with refractory solid tumors.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Florida Cancer Specialists, Sarasota, Florida, United States
University of Oklahoma, Oklahoma City, Oklahoma, United States
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Name: Robert D Mass, MD
Affiliation: MEI Pharma, Inc.
Role: STUDY_CHAIR